Core Viewpoint - The fentanyl concept sector experienced a decline of 0.26% as of the market close on December 24, with several companies within the sector showing significant drops in stock prices [1] Market Performance - The top-performing concept sectors today included: - Terahertz: +4.02% - Commercial Aerospace: +3.60% - Satellite Navigation: +3.47% - Fentanyl: -0.26% [1] Fund Flow Analysis - The fentanyl concept sector saw a net outflow of 63 million yuan from main funds today, with six stocks experiencing significant outflows. The stock with the highest outflow was ST Renfu, which had a net outflow of 42.89 million yuan [1] - Other notable outflows included: - Enhua Pharmaceutical: -13.02 million yuan - Wanfu Biology: -5.15 million yuan - Botao Biology: -2.70 million yuan [1] - Conversely, the stocks with the highest net inflows included: - Guoyao Modern: +1.77 million yuan - Guoyao Shares: +1.47 million yuan [1] Individual Stock Performance - The following stocks within the fentanyl concept sector had notable price changes: - ST Renfu: -2.06% with a turnover rate of 1.92% - Enhua Pharmaceutical: -0.79% with a turnover rate of 0.68% - Wanfu Biology: +0.61% with a turnover rate of 0.51% - Botao Biology: -0.28% with a turnover rate of 0.74% - Guoyao Modern: +0.20% with a turnover rate of 0.51% [1]

Core Insights - The core message of the news is the celebration of the 20th anniversary of Dongfang Biological, highlighting its journey from a startup in Anji, Zhejiang to a significant player in the global in vitro diagnostics field, emphasizing technological innovation, market expansion, and future strategies [1] Group 1: Company History and Development - Dongfang Biological was founded in 2005 in Anji, benefiting from a favorable natural and business environment, which laid the groundwork for its growth [2] - The company established its first overseas subsidiary in the U.S. in 2007, marking its initial foray into international markets [2] - By 2025, Dongfang Biological has achieved 1,688 international certifications across dozens of countries, establishing a robust global presence [2] Group 2: Technological Advancements - The company has focused on technological innovation, evolving from a single product supplier to a comprehensive solution provider with six core technology platforms [3] - Dongfang Biological has developed a product matrix for respiratory testing that includes 126 professional and home testing scenarios, gaining FDA De Novo certification for home testing kits [4] - The company has achieved a total of 2,399 medical device registrations by the end of 2024, showcasing its technological capabilities [3] Group 3: Global Expansion Strategy - Dongfang Biological has established over 50 subsidiaries globally and built a team of nearly 3,000 employees, with a focus on local production and service [5] - The company's global strategy has evolved from "China to Global" to "Global to Global," emphasizing the integration of global resources and local production capabilities [6] - During the COVID-19 pandemic, the company became a major supplier of COVID-19 testing products, demonstrating resilience in its global operations [6] Group 4: Domestic Market Focus and New Ventures - The company is focusing on expanding its domestic market from 2024 to 2025, recognizing the growth potential in China's in vitro diagnostics market [7] - Dongfang Biological is entering the animal health sector, having obtained GMP certificates and production licenses for veterinary drugs, and is developing a range of products for pet diagnostics [8] - The company aims to leverage its multi-technology platforms to provide comprehensive solutions in both human and animal health sectors [8]

Group 1 - Sichuan Chengyu's wholly-owned subsidiary plans to acquire 85% equity of Hubei Jingyi Company for 2.409 billion yuan, enhancing the company's control over highway projects [1] - Huadian Technology signed contracts worth approximately 815 million yuan with Huadian Technology Group for a wind power hydrogen production project [2] - Dongfang Cable and its subsidiary won projects totaling approximately 3.125 billion yuan, accounting for 34.37% of the company's audited revenue for 2024 [3] Group 2 - Heng Rui Medicine received approval for clinical trials of SHR-2906 injection, a self-developed biopharmaceutical aimed at weight control and metabolic regulation [4] - Qingdao Port plans to invest approximately 15.7 billion yuan in two terminal projects [5] - Jingu Co. received a notification to supply low-carbon wheels for two export models to a major domestic car manufacturer, with production expected in 2026 [6] Group 3 - ST Xingguang won a procurement project worth approximately 22.955 million yuan, accounting for 11.96% of the company's revenue for 2024 [7] - Xinbo Co. plans to jointly invest in an alloy materials research institute with partners, focusing on high-performance materials for various industries [8] - Tianqi Lithium's third-phase lithium concentrate expansion project has been completed and is undergoing trial production, with a total capacity of 2.14 million tons per year [9] Group 4 - Changfei Fiber reported that new fiber optic products related to data centers represent a small proportion of total demand [10] - Dongfang Bio's subsidiaries obtained multiple medical device registration certificates, including various testing kits [11] - Xiugang Co. plans to use up to 500 million yuan of idle fundraising for cash management in safe, liquid investment products [12] Group 5 - Jifeng Co. received a project designation for passenger car seat assemblies from a European luxury brand, with a total lifecycle value of approximately 9.8 billion yuan [13] - CanSino initiated Phase I clinical trials for a combined vaccine, completing the first subject enrollment [14] - Dayu Water-saving's subsidiary pre-won a drainage project worth 140 million yuan and another project worth 1 billion yuan [15] Group 6 - Yutong Pharmaceutical's subsidiary received clinical trial approval for YKYY032 injection for treating hyperlipoproteinemia [17] - Diweier announced the departure of a core technical personnel, impacting its technical leadership [18] - Weilang Co.'s controlling shareholder received regulatory measures from the Shandong Securities Regulatory Bureau for failing to fulfill a commitment [19] Group 7 - Xiehe Electronics invested 5 million yuan in a private equity fund focusing on hard technology sectors [20] - Phoenix Optical received a government subsidy of 4.7053 million yuan, representing 35% of its projected net profit for 2024 [21] - China State Construction reported a 0.9% year-on-year increase in new contracts signed in the first 11 months of 2025, totaling 4.0408 trillion yuan [22] Group 8 - Nanguang Energy's pumped storage power station units 1 and 2 have entered trial operation, with units 3 and 4 expected to follow by year-end [23] - Jindalai plans to invest 280 million yuan to acquire a 34% stake in Yunnan Jici Medical Technology [24] - Geer Software terminated its planned acquisition of a majority stake in Weipin Zhiyuan due to failure to reach agreement on key terms [25] Group 9 - Ningbo Fubang completed the absorption merger of its wholly-owned subsidiary, inheriting all assets and liabilities [26] - Zhongyuan Neipei signed a strategic cooperation framework agreement with Ningbo Puzhi Company for humanoid robot-related business [28] - Gongyuan Co. announced a business integration and relocation of its production lines in the East China region [29] Group 10 - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in a comprehensive utilization project for waste salt [30] - Kain Technology announced the departure of a core technical personnel, impacting its research capabilities [31] - ST Renfu received approval for clinical trials of a new drug for idiopathic pulmonary fibrosis [32] Group 11 - Sanbo Brain Science's established brain science fund has completed registration with the Asset Management Association of China [33] - Tongyou Technology plans to apply for a 70 million yuan credit line from Beijing Bank, using its property as collateral [34] - Bai Ao Intelligent signed a significant equipment sales contract worth approximately 27.5021 million yuan [35] Group 12 - ST Xinyan received all restructuring investment funds totaling 2.239 billion yuan, entering the execution phase of its restructuring plan [36] - Dalu Real Estate's subsidiary decided to terminate a planned acquisition of a 60% stake in Beijing Chengzhu Real Estate [38] - Huiyu Pharmaceutical's products received marketing approval in Italy and Norway [39]

证券代码：688298 证券简称：东方生物 公告编号：2025-064 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（简称"东方生物"或"公司"）全资 子公司Healgen Scientific LLC（以下简称"美国衡健"）、哈尔滨东方基因生 物制品有限公司（以下简称"哈尔滨东方基因"）、上海万子健生物科技有限公 司（以下简称"万子健生物"）近日取得以下几款医疗器械产品的注册证书，相 关证书内容公告如下： 产品名称 证书编号 适用国家 预期用途 有效期 持证公司/ 或生产企业 6 项细胞因子检 测试剂盒（流式 荧光发光法） 沪械注准 20252400541 中国 适用于供医疗机构用于体外定量检 测 人 体 血 清 中 细 胞 因 子白 介 素 2 （ IL-2） 、白介素 4（ IL-4） 、 白介素 6（ IL-6） 、白介素 10 （ IL-10）、肿瘤坏死因子α（ TNF- α） 、干扰素γ（ IFN-γ） ...

格隆汇12月19日丨东方生物(688298.SH)公布,公司全资子公司Healgen Scientific LLC、哈尔滨东方基因生 物制品有限公司、上海万子健生物科技有限公司近日取得多项医疗器械产品的注册证书。 ...

Core Viewpoint - The company has obtained multiple medical device registration certificates, enhancing its product portfolio in respiratory testing and related technologies [1] Group 1: Medical Device Registrations - The company's wholly-owned subsidiary, American Hengjian, along with Harbin Oriental Gene and Wanzi Jian Bio, has acquired several medical device registration certificates [1] - The registrations include six cytokine detection kits, testosterone and prolactin testing kits, and international certifications for COVID-19 and influenza antigen combined testing kits [1] Group 2: Market Expansion - The acquisition of these certifications will improve the company's product layout in areas such as respiratory testing, time-resolved fluorescence immunochromatography, flow cytometry, and fluorescence immunoassay instruments [1] - This development is expected to facilitate the overall market expansion of related technology platform products [1] Group 3: Sales Performance - Actual sales performance will depend on the competitiveness of the products and the company's market sales capabilities [1] - Currently, it is not possible to predict the impact of these developments on the company's future operating performance [1]

Core Viewpoint - Dongfang Biological (688298.SH) reported a slight increase in revenue for the first three quarters of 2025, but continued to face net losses, indicating ongoing financial challenges despite some improvements in cash flow [1]. Financial Performance - The company achieved an operating revenue of 672 million yuan in the first three quarters of 2025, representing a year-on-year increase of 2.16% [1]. - The net profit attributable to shareholders was -213 million yuan, an improvement from -262 million yuan in the same period last year [1]. - The net profit excluding non-recurring gains and losses was -232 million yuan, compared to -350 million yuan in the previous year [1]. - The net cash flow from operating activities was -155 million yuan, an improvement from -367 million yuan year-on-year [1]. Future Projections - For 2024, Dongfang Biological expects to achieve an operating revenue of 828 million yuan, a year-on-year growth of 0.95% [4]. - The projected net profit attributable to shareholders is -529 million yuan, worsening from -398 million yuan in the previous year [4]. - The net profit excluding non-recurring gains and losses is expected to be -571 million yuan, compared to -431 million yuan in the prior year [4]. - The net cash flow from operating activities is projected to be -348 million yuan, an improvement from -1.646 billion yuan in the previous year [4]. Capital Raising - Dongfang Biological raised a total of 637.5 million yuan from its public offering, with a net amount of 550.8 million yuan after expenses [5]. - The final net amount raised was 10.82 million yuan less than originally planned [5]. - The funds are intended for projects including the production of rapid diagnostic products, technology research and development, and the establishment of a marketing network [5].

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

浙江东方基因生物制品股份有限公司 证券代码：688298 证券简称：东方生物 公告编号：2025-063 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 20 日 （二） 股东会召开的地点：浙江省湖州市安吉县递铺街道阳光大道东段东方基 因会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 102 | | --- | --- | | 普通股股东人数 | 102 | | 2、出席会议的股东所持有的表决权数量 | 100,010,751 | | 普通股股东所持有表决权数量 | 100,010,751 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 52.2536% | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 52.25 ...